Welcome to our dedicated page for Intelligent Bio Solutions news (Ticker: INBS), a resource for investors and traders seeking the latest updates and insights on Intelligent Bio Solutions stock.
Intelligent Bio Solutions Inc. develops medical technology for rapid, non-invasive testing, centered on fingerprint sweat drug screening. Its updates commonly cover the Intelligent Fingerprinting Drug Screening System, Drug Screening Cartridges, DSR-Plus reader, lateral-flow test strip manufacturing, and the reader-and-consumable sales model used in workplace testing markets outside the United States.
Company news also focuses on clinical and regulatory work supporting an FDA 510(k) pathway for codeine detection, cybersecurity and validation testing tied to the system, European patent protection for fingerprint chemical analysis, manufacturing scale-up for readers and cartridges, customer deployments in the United Kingdom, and periodic revenue reports by product category.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Intelligent Bio Solutions Inc. (Nasdaq: INBS) has announced its collaboration with Dodman Limited, a UK manufacturer, to implement the Intelligent Fingerprinting Drug Screening System for workplace drug testing. This system offers a non-invasive alternative to traditional urine tests by analyzing fingerprint sweat samples. It enables quick on-site testing, yielding results in under ten minutes. Dodman aims to enhance its health and safety reputation by proactively introducing random drug testing across its operations.
Dodman's Health and Safety Manager, Chris Davies, emphasized the benefits of this approach, noting improved safety and differentiation in the market. Intelligent Bio Solutions recognizes the increasing importance of drug testing for employee safety and offers an innovative solution that is both efficient and accurate.